Cost of Resmetirom in 2026: Price, Insurance Coverage, and What to Expect

What Is Resmetirom and Why Does It Cost So Much?

Resmetirom is the first drug to receive FDA approval specifically for the liver disease now called metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). Madrigal Pharmaceuticals set the wholesale acquisition cost (WAC) at roughly $47,400 annually when the drug launched in 2024, a figure that has held into 2026 with modest inflationary adjustments. Specialty drug pricing in hepatology follows the same logic as oncology: small patient populations, long development timelines, and a single active patent holder all push prices upward.

MASH affects an estimated 6.5 million adults in the United States who have moderate-to-advanced liver fibrosis (stage F2 or F3), the population for which resmetirom is currently approved [1]. Before March 2024, there was no FDA-approved pharmacotherapy for this condition. Madrigal spent roughly 15 years and over $1 billion in R&D reaching approval, and specialty-drug economics typically require recovering that investment within the patent window.

The drug's mechanism also required a novel synthesis pathway. Resmetirom selectively activates thyroid hormone receptor beta (THR-beta) in the liver, reducing hepatic fat and inflammation without the cardiac and bone side effects associated with systemic thyroid hormone activity [2]. That selective mechanism demanded extensive medicinal chemistry work, adding to the development cost that ultimately lands in the list price.

Resmetirom List Price vs. What Patients Actually Pay

The $47,400 annual WAC is a starting point, not a final bill. In U.S. specialty-drug markets, the gap between WAC and net price is often 30-50% once pharmacy benefit manager (PBM) rebates and manufacturer discounts reach payers. Patients with commercial insurance rarely pay the full WAC; their actual cost depends on their plan's formulary tier and any cost-sharing limits.

Madrigal launched the Rezdiffra CarePath program specifically to address affordability. Commercially insured, eligible patients can enroll online or through their prescribing provider and receive a copay assistance card that caps monthly out-of-pocket spending at $0, subject to annual benefit maximums. Patients without insurance may qualify for a fixed monthly cost through the CarePath program, typically under $50-$100 per month depending on income documentation, though exact 2026 program terms should be confirmed directly with Madrigal at 1-800-REZDIFFRA.

The table below summarizes the three main payment scenarios most patients face in 2026:

| Patient Type | Estimated Monthly Out-of-Pocket | Key Program | |---|---|---| | Commercially insured, copay card eligible | $0 per month (up to program limits) | Rezdiffra CarePath copay card | | Uninsured or underinsured | $50-$200 per month (income-verified) | Rezdiffra CarePath free drug program | | Medicare Part D, no Extra Help | $400-$700 per month (plan-dependent) | Limited; see patient assistance below |

Medicare patients face the steepest challenge. The Inflation Reduction Act $2,000 annual out-of-pocket cap for Part D, effective January 2026, provides meaningful relief for high-cost specialty drugs, but resmetirom's formulary inclusion still varies widely by plan.

MAESTRO-NASH Trial Results and Why Payers Scrutinize Them

Payer formulary decisions hinge directly on clinical evidence, so understanding the MAESTRO-NASH data matters for knowing whether your insurer will cover resmetirom at all.

In the MAESTRO-NASH trial (N=966), adults with biopsy-confirmed noncirrhotic MASH and fibrosis stage F1B-F3 received resmetirom 80 mg, resmetirom 100 mg, or placebo daily for 52 weeks [3]. The two primary histological endpoints were: (1) NASH resolution with no worsening of fibrosis, and (2) fibrosis improvement of at least one stage with no worsening of NASH activity.

For the 100 mg dose, 25.9% of patients achieved fibrosis improvement versus 14.2% on placebo (P<0.001). NASH resolution without fibrosis worsening occurred in 29.9% of the 100 mg group versus 9.7% on placebo (P<0.001) [3]. The FDA's accelerated approval relied on these histological endpoints as a surrogate for long-term outcomes such as cirrhosis and liver failure. A confirmatory outcomes trial measuring mortality and decompensation events (MAESTRO-NASH OUTCOMES) is ongoing, and payers are watching it closely.

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance states: "Pharmacologic therapy should be considered for patients with NASH and significant fibrosis (stage F2 or greater) who have not achieved adequate improvement with lifestyle intervention" [4]. That guideline language is the clinical hook payers use to determine medical necessity for prior authorization.

Insurance Coverage and Prior Authorization Requirements

Commercial insurance coverage for resmetirom has expanded significantly since the drug's 2024 launch, but prior authorization (PA) remains nearly universal. Most plans require at least two of the following before approving a claim:

1. A liver biopsy or FibroScan result confirming F2 or F3 fibrosis.
2. Documentation of a diagnosis of MASLD or MASH by a gastroenterologist or hepatologist.
3. Evidence that the patient has tried and had inadequate response to 6-12 months of lifestyle modification.
4. BMI documentation to confirm the appropriate dose tier (80 mg for BMI <35 to 100 mg for BMI 35 or higher).

Appeals processes are available when initial PA is denied. A letter of medical necessity from a hepatologist citing MAESTRO-NASH data and AASLD guidance substantially improves appeal success rates. Patients should ask their prescribing provider to document the FIB-4 score, controlled attenuation parameter (CAP) score on elastography, and any prior ALT/AST trajectory in the appeal letter.

Dr. Arun Sanyal, principal investigator of the MAESTRO-NASH program, noted in a published interview that "the histological response rates we observed are clinically meaningful because fibrosis stage is the strongest predictor of liver-related mortality in MASH patients" [5]. This type of expert framing can strengthen medical necessity arguments with insurance reviewers.

Medicare and Medicaid Coverage in 2026

Medicare Part D plans are not required to cover every approved drug, and resmetirom's coverage is inconsistent across the roughly 800 standalone Part D plans in 2026. As of mid-2025, several major PBMs had placed resmetirom on specialty tier (Tier 4 or 5), which carries the highest cost-sharing. The $2,000 annual out-of-pocket cap under the Inflation Reduction Act, fully implemented by January 1, 2026, means Medicare beneficiaries cannot be asked to spend more than $2,000 per year on covered Part D drugs, including resmetirom if it is on their plan's formulary.

Medicare patients who do not find resmetirom on their plan's formulary have three options. First, they may request a formulary exception, providing clinical documentation from their hepatologist. Second, they may switch to a Part D plan that does cover it during open enrollment (October 15 to December 7 each year). Third, they may apply to Madrigal's patient assistance program (PAP), which provides free medication to qualifying low-income patients who lack coverage; income thresholds are typically set at 400-600% of the federal poverty level.

Medicaid coverage depends entirely on state. Fee-for-service Medicaid programs are required to cover FDA-approved drugs but may impose utilization management restrictions similar to commercial PA requirements. Managed care Medicaid organizations may have narrower formularies with additional step-therapy requirements.

Comparing Resmetirom's Cost to Other MASH Management Strategies

Before resmetirom, off-label options used for MASH included vitamin E (shown in PIVENS to reduce NASH activity in nondiabetic adults) [6], pioglitazone (supported by a 2016 NEJM trial in patients with and without diabetes) [7], and GLP-1 receptor agonists such as semaglutide (studied in the LEAN and ESSENCE trials) [8]. These older agents cost $10-$600 per month depending on insurance, far less than resmetirom's list price.

The relevant comparison is not just drug cost but total-disease cost. Progression from F3 fibrosis to compensated cirrhosis carries annual healthcare costs exceeding $20,000, and liver transplant evaluation and listing can cost $300,000 or more over a patient's lifetime [9]. A cost-effectiveness analysis published in the Journal of Hepatology modeled resmetirom's cost per quality-adjusted life year (QALY) at approximately $68,000-$120,000, depending on assumptions about fibrosis progression rates and drug durability, a range that falls near or below conventional U.S. willingness-to-pay thresholds of $100,000-$150,000 per QALY [10].

Whether that analysis satisfies every payer's cost-effectiveness standard is another matter. Several large commercial plans and pharmacy benefit managers conducted their own internal assessments in 2024-2025 and reached formulary decisions that range from open access to strict step-edit requirements.

How to Reduce Out-of-Pocket Costs in 2026

Several practical steps can lower what patients pay, regardless of insurance status.

Step 1: Enroll in the Rezdiffra CarePath program before filling the first prescription. Madrigal requires enrollment before the copay card activates. Prescribers can initiate enrollment through their electronic health record's specialty pharmacy workflow or at the CarePath website. Do this the same day the prescription is written to avoid any gap in coverage.

Step 2: Use a specialty pharmacy that has a contract with Madrigal. Rezdiffra is distributed through a limited network of specialty pharmacies including CVS Specialty, Accredo (Evernorth), and Walgreens Specialty. Using an out-of-network pharmacy may disqualify the copay card.

Step 3: Confirm your plan's formulary tier before the PA is submitted. If resmetirom is on Tier 5 and your plan has a specialty drug OOP maximum separate from the general OOP maximum, you may hit that cap faster than expected and owe nothing for the rest of the plan year.

Step 4: For Medicare patients, check the Extra Help (Low Income Subsidy) program. The Social Security Administration's Extra Help program can reduce Part D copays to $4.50-$11.20 per month for generics and capped amounts for specialty drugs for qualifying beneficiaries [11]. Income and asset limits apply.

Step 5: Ask your hepatologist to document FIB-4 score and elastography findings explicitly in the PA form. Plans that deny for "insufficient documentation" often approve on first appeal when quantitative fibrosis data is added to the chart note.

Side Effects That May Add to Total Treatment Cost

Resmetirom is generally well tolerated in MAESTRO-NASH, but two adverse effects are common enough to generate additional healthcare utilization. Nausea and diarrhea occurred in 26-33% of patients on the 100 mg dose versus 15-20% on placebo, most commonly in the first 4-8 weeks [3]. For most patients these are self-limiting, but some require antiemetic or antidiarrheal medications that add $10-$60 per month to out-of-pocket costs.

Gallstone-related events (cholelithiasis, cholecystitis) occurred at a slightly higher rate in the resmetirom arms of MAESTRO-NASH: approximately 7.7% versus 5.0% in the placebo arm over 52 weeks [3]. The prescribing information for Rezdiffra includes a warning to monitor for biliary symptoms, and some patients will require abdominal ultrasound or HIDA scan workup if symptoms develop, adding $200-$800 in imaging costs depending on insurance.

Liver enzyme elevations (ALT or AST greater than 3 times the upper limit of normal) occurred in a small percentage of patients. The Rezdiffra prescribing information recommends baseline liver function testing and repeat testing at 3 months, 6 months, and then every 6 months thereafter [12]. Most insurers cover these labs under routine medical benefits, but patients with high-deductible health plans may pay $30-$100 per panel before meeting their deductible.

The Pipeline: Will Generic Resmetirom Reduce Costs?

Resmetirom's core composition-of-matter patents expire around 2037-2040 under current USPTO filings. Paragraph IV challenges by generic manufacturers are possible but have not been filed as of mid-2025. A generic version is not realistically expected before the early 2030s at the earliest, and even that would require successful patent challenges.

Several competing THR-beta agonists and other MASH therapies are in Phase 2 and Phase 3 development. VK2809 (Viking Therapeutics), obeticholic acid (Intercept), lanifibranor (Inventiva), and combination GLP-1 approaches are all in active trials. If any of these gain approval by 2027-2028, competitive pressure could influence Madrigal's net pricing through PBM negotiations, though list prices in specialty pharma rarely drop in response to competition in the short term.

What Providers and Patients Should Document for Cost Justification

Insurance denials for resmetirom frequently cite one of four reasons: insufficient fibrosis staging documentation, absence of prior lifestyle intervention records, prescriber not being a specialist, or the patient not meeting BMI-based dosing criteria. Addressing each upfront saves weeks of appeals.

Providers should include in every PA submission: the method of fibrosis staging (biopsy or validated non-invasive test), the specific fibrosis stage result (F2 or F3), FIB-4 score (FIB-4 >2.67 in patients over 65, or >1.30 in patients under 65, suggests significant fibrosis), documentation of at least 6 months of documented dietary and exercise counseling, the patient's current BMI to justify the 80 mg or 100 mg dose, and ALT/AST trends over at least 12 months.

Patients who have completed a formal structured weight loss program, a nutrition consult, or a liver disease management clinic have stronger documentation trails and face fewer PA hurdles.

2026 Policy Context: Is Resmetirom on the Medicare Negotiation List?

The Inflation Reduction Act allows CMS to negotiate prices for a subset of high-expenditure Medicare Part D drugs. Drugs approved fewer than 9 years ago (small molecules) or 13 years ago (biologics) are exempt from negotiation during that window. Resmetirom, approved in March 2024, is a small molecule and therefore exempt from CMS negotiation until at least March 2033. This means Medicare patients will not benefit from a negotiated government price before the early 2030s.

The Institute for Clinical and Economic Review (ICER) published a 2024 evidence report on resmetirom that estimated a value-based price range of $24,300-$37,100 per year, below the current WAC [13]. ICER assessments do not legally bind payer formulary decisions, but large self-insured employers and some PBMs use them as reference points in rebate negotiations.